Nimbus COVID-19 - Revision history

Blossom: Blossom moved page Nimbus Covid Variant to Nimbus COVID-19

2025-06-14T13:09:47Z

Blossom moved page Nimbus Covid Variant to Nimbus COVID-19

← Older revision	Revision as of 19:09, 14 June 2025
(No difference)

Blossom at 13:09, 14 June 2025

2025-06-14T13:09:38Z

← Older revision		Revision as of 19:09, 14 June 2025
Line 1:		Line 1:
	~~{{Infobox virus variant~~
	~~\| name = Nimbus COVID-19 variant~~
	~~\| image =~~
	~~\| virus = SARS-CoV-2~~
	~~\| lineage = Omicron subvariant (NB.1.8.1)~~
	~~\| first_detected = Early 2025~~
	~~\| location_first_detected = United States~~
	~~\| transmission = High~~
	~~\| symptoms = Sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, diarrhea~~
	~~\| vaccine_effectiveness = Vaccines remain effective against severe illness~~
	~~\| treatment = Antiviral medications such as nirmatrelvir effective~~
	}}

	The '''Nimbus COVID-19 variant''' (designated NB.1.8.1) is a subvariant of the SARS-CoV-2 Omicron lineage that emerged in early 2025. It has been identified in multiple U.S. states, including New York, New Jersey, and Massachusetts, and has become one of the more prevalent strains in the country.		The '''Nimbus COVID-19 variant''' (designated NB.1.8.1) is a subvariant of the SARS-CoV-2 Omicron lineage that emerged in early 2025. It has been identified in multiple U.S. states, including New York, New Jersey, and Massachusetts, and has become one of the more prevalent strains in the country.

	== Virology ==		==Virology==
	Nimbus contains mutations in the spike protein, which are believed to increase transmissibility and enable partial evasion of antibody responses. Despite these mutations, the World Health Organization (WHO) has assessed the global public health risk of Nimbus as low, citing no evidence of increased severity, hospitalization rates, or mortality compared to other circulating variants.		Nimbus contains mutations in the spike protein, which are believed to increase transmissibility and enable partial evasion of antibody responses. Despite these mutations, the World Health Organization (WHO) has assessed the global public health risk of Nimbus as low, citing no evidence of increased severity, hospitalization rates, or mortality compared to other circulating variants.

	== Clinical Features ==		==Clinical Features==
	Symptoms of Nimbus infection are generally consistent with previous COVID-19 variants and include sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, and diarrhea. Some individuals have reported a particularly severe sore throat sensation described as feeling like "razor blades."		Symptoms of Nimbus infection are generally consistent with previous COVID-19 variants and include sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, and diarrhea. Some individuals have reported a particularly severe sore throat sensation described as feeling like "razor blades."

	== Prevention and Treatment ==		==Prevention and Treatment==
	Existing COVID-19 vaccines continue to provide strong protection against severe illness caused by the Nimbus variant. Antiviral treatments, including nirmatrelvir, remain effective against this strain. Public health authorities recommend that vulnerable populations—such as older adults and immunocompromised individuals—stay up to date with booster vaccinations to maintain optimal protection.		Existing COVID-19 vaccines continue to provide strong protection against severe illness caused by the Nimbus variant. Antiviral treatments, including nirmatrelvir, remain effective against this strain. Public health authorities recommend that vulnerable populations—such as older adults and immunocompromised individuals—stay up to date with booster vaccinations to maintain optimal protection.

	== Public Health Response ==		==Public Health Response==
	Health experts advocate for continued precautions to reduce transmission of Nimbus, including hand hygiene, mask use in crowded or high-risk settings, and vaccination, especially during periods of increased travel and social gatherings.		Health experts advocate for continued precautions to reduce transmission of Nimbus, including hand hygiene, mask use in crowded or high-risk settings, and vaccination, especially during periods of increased travel and social gatherings.

	== References ==		==References==
	{{Reflist}}		{{Reflist}}

	== External Links ==		==External Links==
	* [CT Insider article on Nimbus variant](https://www.ctinsider.com/health/article/nimbus-covid-variant-2025-symptoms-vaccine-ct-20375921.php?utm_source=chatgpt.com)		*[CT Insider article on Nimbus variant](https://www.ctinsider.com/health/article/nimbus-covid-variant-2025-symptoms-vaccine-ct-20375921.php?utm_source=chatgpt.com)
	* [Wired article on WHO monitoring Nimbus](https://www.wired.com/story/who-monitors-new-covid-variant-nb181-spread-america-europe-nimbus?utm_source=chatgpt.com)		*[Wired article on WHO monitoring Nimbus](https://www.wired.com/story/who-monitors-new-covid-variant-nb181-spread-america-europe-nimbus?utm_source=chatgpt.com)
	* [People article on severe sore throat symptom](https://people.com/sore-throat-feels-like-razor-blades-new-covid-variant-nb-181-nimbus-11752661?utm_source=chatgpt.com)		*[People article on severe sore throat symptom](https://people.com/sore-throat-feels-like-razor-blades-new-covid-variant-nb-181-nimbus-11752661?utm_source=chatgpt.com)

	{{COVID-19 pandemic}}		{{COVID-19 pandemic}}

Blossom: Created page with "{{Infobox virus variant | name = Nimbus COVID-19 variant | image = | virus = SARS-CoV-2 | lineage = Omicron subvariant (NB.1.8.1) | first_detected = Early 2025 | location_first_detected = United States | transmission = High | symptoms = Sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, diarrhea | vaccine_effectiveness = Vaccines remain effective against severe illness | treatment = Antiviral medications suc..."

2025-06-14T13:09:25Z

Created page with "{{Infobox virus variant | name = Nimbus COVID-19 variant | image = | virus = SARS-CoV-2 | lineage = Omicron subvariant (NB.1.8.1) | first_detected = Early 2025 | location_first_detected = United States | transmission = High | symptoms = Sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, diarrhea | vaccine_effectiveness = Vaccines remain effective against severe illness | treatment = Antiviral medications suc..."

New page

{{Infobox virus variant
| name = Nimbus COVID-19 variant
| image =
| virus = SARS-CoV-2
| lineage = Omicron subvariant (NB.1.8.1)
| first_detected = Early 2025
| location_first_detected = United States
| transmission = High
| symptoms = Sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, diarrhea
| vaccine_effectiveness = Vaccines remain effective against severe illness
| treatment = Antiviral medications such as nirmatrelvir effective
}}

The '''Nimbus COVID-19 variant''' (designated NB.1.8.1) is a subvariant of the SARS-CoV-2 Omicron lineage that emerged in early 2025. It has been identified in multiple U.S. states, including New York, New Jersey, and Massachusetts, and has become one of the more prevalent strains in the country.

== Virology ==
Nimbus contains mutations in the spike protein, which are believed to increase transmissibility and enable partial evasion of antibody responses. Despite these mutations, the World Health Organization (WHO) has assessed the global public health risk of Nimbus as low, citing no evidence of increased severity, hospitalization rates, or mortality compared to other circulating variants.

== Clinical Features ==
Symptoms of Nimbus infection are generally consistent with previous COVID-19 variants and include sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, and diarrhea. Some individuals have reported a particularly severe sore throat sensation described as feeling like "razor blades."

== Prevention and Treatment ==
Existing COVID-19 vaccines continue to provide strong protection against severe illness caused by the Nimbus variant. Antiviral treatments, including nirmatrelvir, remain effective against this strain. Public health authorities recommend that vulnerable populations—such as older adults and immunocompromised individuals—stay up to date with booster vaccinations to maintain optimal protection.

== Public Health Response ==
Health experts advocate for continued precautions to reduce transmission of Nimbus, including hand hygiene, mask use in crowded or high-risk settings, and vaccination, especially during periods of increased travel and social gatherings.

== References ==
{{Reflist}}

== External Links ==
* [CT Insider article on Nimbus variant](https://www.ctinsider.com/health/article/nimbus-covid-variant-2025-symptoms-vaccine-ct-20375921.php?utm_source=chatgpt.com)
* [Wired article on WHO monitoring Nimbus](https://www.wired.com/story/who-monitors-new-covid-variant-nb181-spread-america-europe-nimbus?utm_source=chatgpt.com)
* [People article on severe sore throat symptom](https://people.com/sore-throat-feels-like-razor-blades-new-covid-variant-nb-181-nimbus-11752661?utm_source=chatgpt.com)

{{COVID-19 pandemic}}

{{SARS-CoV-2 variants}}

[[Category:COVID-19 pandemic]]
[[Category:SARS-CoV-2 variants]]
[[Category:2025 introductions]]